Targeting FOXM1 /Cystathionine‐β‐Synthase Axis by Brusatol Inhibits Lung Cancer Malignant Progression
Phytotherapy Research · 2026
DOI: 10.1002/ptr.70243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, 2026. Verfasst von Yutong Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China. Hauptthemen laut MEDLINE: Quassins, Lung Neoplasms, Forkhead Box Protein M1. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
Brusatol (BRU), an extract derived from Brucea javanica, has been shown to exert antitumor effects on various cancers, including lung cancer. However, its downstream molecular targets and the underlying mechanisms in lung cancer remain to be fully elucidated. Label‐free quantitative proteomic analysis was used to identify the altered proteins in response to Brusatol treatment. The colony formation, Propidium iodide (PI) staining, and CCK8 were applied to detect cell proliferation, apoptosis, and cytotoxicity. Western blot and qRT‐PCR were used to detect the expression of FOXM1 and CBS. The interaction between Brusatol and FOXM1 was validated by Streptavidin (SA)‐based pulldown, Cellular Thermal Shift Assay, and molecular docking. In this study, we demonstrated that Brusatol directly interacts with FOXM1, leading to its degradation, thereby suppressing the malignant progression of lung cancer both in vitro and in vivo. Furthermore, our findings revealed that FOXM1 binds to the promoter region of Cystathionine beta‐synthase (CBS) and enhances its expression in lung cancer cells. In addition, we evaluated the antitumor effects of Brusatol using a patient‐derived organoid (PDO) model of lung cancer and observed that Brusatol significantly reduced cell viability, induced cell death, and downregulated the expression of both FOXM1 and CBS in PDOs. Moreover, a positive correlation between FOXM1 and CBS expression was identified in lung cancer. Taken together, our results indicate that Brusatol functions as a novel FOXM1 inhibitor and inhibits lung cancer progression by blocking the activation of the FOXM1/CBS signaling axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
- Department of Respiration, School of Medicine, the Sixth Affiliated Hospital, South China University of Technology (Nanhai District People's Hospital of Foshan), Foshan, China.
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
- Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
- Department of Clinical Laboratory, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research &The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Chuanchun Han
Zitieren
APA
Wu, Y., Feng, H., Wang, Y., Tian, L., Han, C., Yan, L., Song, J., & Shen, D. (2026). Targeting FOXM1 /Cystathionine‐β‐Synthase Axis by Brusatol Inhibits Lung Cancer Malignant Progression. Phytotherapy Research. https://doi.org/10.1002/ptr.70243
Vancouver
Wu Y, Feng H, Wang Y, Tian L, Han C, Yan L, et al. Targeting FOXM1 /Cystathionine‐β‐Synthase Axis by Brusatol Inhibits Lung Cancer Malignant Progression. Phytotherapy Research. 2026. doi:10.1002/ptr.70243
BibTeX
@article{Wu2026,
author = {Wu, Yutong and Feng, Haipeng and Wang, Yichuan and Tian, Lili and Han, Chuanchun and Yan, Linping and Song, Jing and Shen, Dachuan},
title = {Targeting FOXM1 /Cystathionine‐β‐Synthase Axis by Brusatol Inhibits Lung Cancer Malignant Progression},
journal = {Phytotherapy Research},
year = {2026},
doi = {10.1002/ptr.70243}
}
EUVIMED